Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02CFR
|
|||
Former ID |
DIB006237
|
|||
Drug Name |
GW-559768X
|
|||
Synonyms |
GW-569998X; GW-578257A; GW-585550A; RET tyrosine kinase inhibitors (cancer); RET tyrosine kinase inhibitors (cancer), GlaxoSmithKline
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
Company |
GlaxoSmithKline plc
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [1] |
KEGG Pathway | Endocytosis | |||
Pathways in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
Posttranslational regulation of adherens junction stability and dissassembly | ||||
WikiPathways | SIDS Susceptibility Pathways | |||
Dopaminergic Neurogenesis |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.